Floatz logo

Atlcar.Cd30.Ccr4 Cells

Lymphomatoid Papulosis

UNC Lineberger Comprehensive Cancer CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Lymphomatoid Papulosis cohort.

Asset / SponsorPhaseRating
Brentuximab Vedotin
Memorial Sloan Kettering Cancer Center
Phase 2B
cc-5013
John Reneau
Phase 2B
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC
Bendamustine
UNC Lineberger Comprehensive Cancer Center
Phase 1CC
Triamcinalone
Case Comprehensive Cancer Center
N/AD
Nitrogen Mustard
Case Comprehensive Cancer Center
N/AD
Bexarotene
Case Comprehensive Cancer Center
N/AD

Same molecule, other indications

Atlcar.Cd30.Ccr4 Cells is also rated in:

immune system disorderDormant
CC
Indicative ·
43 / 100
View asset →
immunoproliferative disorderDormant
CC
Indicative ·
43 / 100
View asset →
lymphatic system disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →